Characteristics of lymphoma SLE cases and the cancer-free SLE controls
| Characteristic | Lymphoma cases (n=75) | Cancer-free (n=4961) |
|---|---|---|
| Age at entry (years), mean (SD)* | 45.2 (14.5) | 38.5 (13.8) |
| Female | 60 (80.0) | 4511 (90.9) |
| White | 53 (70.0) | 3049 (61.5) |
| Sjogren's syndrome | 16 (21.3) | 983 (19.8) |
| Disease duration at entry (years), mean (SD)† | 6.2 (8.1) | 6.2 (7.5) |
| Disease activity at entry, mean (SD)‡ | 5.2 (4.9) | 6.3 (6.6) |
| Glucocorticosteroids ever used§ | 58 (77.3) | 3959 (79.8) |
| Cyclophosphamide ever used | 15 (20.0) | 834 (16.8) |
| Azathioprine ever used | 19 (25.3) | 1717 (34.6) |
| Methotrexate ever used | 9 (12.0) | 960 (19.4) |
| Mycophenolate mofetil ever used | 6 (8.0) | 884 (17.8) |
| Antimalarial drugs ever used¶ | 55 (73.3) | 4022 (81.1) |
Unless otherwise indicated, values are number (%).
*Median age was 47.3 in lymphoma cases and 37.1 in controls.
†Median disease duration at cohort entry was 3.1 for cases and 3.5 for controls.
‡SLE Disease Activity Index-2K (SLEDAI-2K); median value was 4 for both cases and controls.
§Only systemic steroid exposures were included.
¶Antimalarial drugs included hydroxycholoroquine and chloroquine.
SLE, systemic lupus erythematosus.